Nivolumab  has been rejected on cost-effectiveness grounds for melanoma. Further assessment is ongoing for its use in kidney cancer

A cancer drug considered too expensive for the Irish health service has been found to significantly extend survival rates for patients with kidney can(...)

Cystic fibrosis  campaigner said the decision to reject Orkambi  on cost effectiveness grounds was  disappointing.  Photograph: Alan Betson/The Irish Times

Cystic fibrosis patients have expressed disappointment after a “game-changing” drug was rejected on cost effectiveness grounds. Orkambi, which greatl(...)

Minister for Health Simon Harris asked for a report this week on the HSE deliberations on new cancer drugs. Photograph: Gareth Chaney/Collins

The HSE is expected to make a new cancer drug available free to patients with melanoma. Pembrolizumab should be included in the State drugs scheme fo(...)

Pharmaceutical giant Bristol-Myers Squibb is to provide a life-saving new cancer drug on a compassionate basis to Irish patients for another month. File photograph: Getty Images

The makers of a life-saving new cancer drug are to provide it on a compassionate basis to Irish patients for another month. Pharmaceutical giant Bris(...)

  • « First
  • Prev
  • 2
  • 3
  • 4
  • 5